Table 2.
Association between Exosomal CA1 Expression Level and Clinicopathological Features of DLBCL Patients
| Characteristics | No. | Low | High | p Value |
|---|---|---|---|---|
| Sex | >0.05 | |||
| Male | 66 | 30 | 36 | |
| Female | 46 | 25 | 21 | |
| Age (years) | >0.05 | |||
| <60 | 71 | 34 | 37 | |
| ≥60 | 41 | 21 | 20 | |
| Subtype | >0.05 | |||
| ABC | 59 | 27 | 32 | |
| GCB | 53 | 28 | 25 | |
| B symptoms | >0.05 | |||
| Absent | 96 | 46 | 50 | |
| Present | 16 | 9 | 7 | |
| LDH | >0.05 | |||
| Normal | 74 | 34 | 40 | |
| Elevated | 38 | 21 | 17 | |
| Ann Arbor stage | >0.05 | |||
| I+II | 58 | 26 | 32 | |
| III+IV | 54 | 29 | 25 | |
| IPI score | 0.004 | |||
| Low-risk group | 67 | 39 | 28 | |
| Low- to medium-risk group | 24 | 13 | 11 | |
| High- to medium-risk group | 13 | 1 | 12 | |
| High-risk group | 8 | 2 | 6 |
ABC, activated B cell subtype; DLBCL, diffuse large B cell lymphoma; GCB, germinal center B cell subtype; IPI, international prognostic index; LDH, lactate dehydrogenase.